gynecomastia/vomiting

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 18 rezilta yo

Nerve stimulator-guided thoracic paravertebral block for gynecomastia surgery.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Thoracic paravertebral block (TPVB) is gaining popularity for female breast surgeries due to various advantages like less nausea and vomiting and better post-operative pain relief, which helps in early ambulation and discharge from the hospital. Use of nerve stimulator during this block has further

Estramustine phosphate (Estracyt) treatment of T3-T4 prostatic carcinoma.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

From September, 1978, to November, 1980, 69 consecutive patients with locally advanced (T3-T4) prostatic adenocarcinoma, with or without distant metastases, were treated with oral estramustine phosphate. Dosage was 15 mg/kg/day for 2 months, followed by 5 mg/kg/day until progression. In the 48

Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Goserelin acetate implant is a newly approved depot formulation of a luteinizing hormone-releasing hormone (LHRH) agonist indicated for palliation of advanced prostate cancer. LHRH superagonists suppress gonadotropin release from the pituitary gland by causing down-regulation of receptors. The

Hormonal treatment for prostate cancer in Italy. Preliminary data from a survey of the QUABIOS Group.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE An observational study was planned by the QUABIOS group, to survey the hormonal modalities administered to prostate cancer patients in Italy within a time window of 12 months. We report here a summary of treatment schedules and related adverse effects, as recorded at the first

Comparison of ketoconazole and estramustine for treating patients with castration-resistant prostate cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE We investigated the efficacy of ketoconazole and estramustine before chemotherapy for treating patients with progressive castration-resistant prostate cancer (CRPC) after anti-androgen withdrawal syndrome. METHODS Eighty-four patients who were diagnosed with CRPC and were treated between

Prostatic cancer and SCH-13521: II. Histological alterations and the pituitary gonadal axis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

We herein report on the results of treatment of 13 men with stage D prostatic carcinoma with a non-steroidal compound, SCH-13521 (flutamide). The dosage of the drug was 750 mg. in 3 divided doses daily and treatment extended for 2 to 20 months. Two patients failed to respond in any fashion, 7 had

The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Our aim was to determine whether domperidone could improve the symptoms of patients with gastroparesis, accelerate gastric emptying, and enhance quality of life. METHODS Seventeen patients (13 women, 4 men; mean age 42.9 yr) with documented gastroparesis were evaluated. A baseline gastric

Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The efficacy and tolerability of a long term treatment (21-53 months; mean, 36) with a new injectable form of bromocriptine (Parlodel LAR, Sandoz) was assessed in 13 patients (9 males and 4 females, aged 14-68 yr) with macroprolactinoma. Parlodel LAR was administered deeply im once monthly, with 50

Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Despite the favorable toxicity profile at the standard dose of 560 mg daily, the tolerability and toxicology of estramustine phosphate (EMP) have been a cause for concern at administration. Moreover, we do not know whether a lower dose of 280 mg of EMP daily can be administered with some efficacy

Metastatic bronchogenic carcinoma with human chorionic gonadotropin production manifesting as cerebellar hemorrhage--case report.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A 58-year-old male presented with a rare case of brain metastatic bronchogenic carcinoma with human chorionic gonadotropin (hCG) production causing cerebellar hemorrhage with symptoms of nausea, vomiting, and headache. Bronchogenic carcinoma manifesting as gynecomastia had been resected a few months

Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In a randomized, prospective trial, 199 previously untreated patients with Stage D2 prostatic cancer were treated with 3 mg/day diethylstilbestrol (DES) or 1 mg/day leuprolide acetate, a luteinizing hormone releasing hormone analog. Both DES and leuprolide suppressed testosterone to the desired

[An epidemiologic study of the prevalence of alcohol consumption in the Council of Tineo (Asturias)].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To know the incidence and prevalence of alcohol consumption in the studied area and also the somatometric alterations and laboratory findings found. METHODS One prospective study was performed in one-way, transversal in a sample of 216 people. With a protocol we collect the data of alcohol

Do perceptions of adverse events differ between patients and physicians? Findings from a randomized, controlled trial of radical treatment for prostate cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Previous cross-sectional studies show considerable discrepancies between patient and physician ratings of adverse events after prostate cancer treatment. We used data from a randomized, controlled trial to examine such discrepancies. METHODS The Scandinavian Prostate Cancer Groups Study 7

[Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The phase II study of flutamide, a pure anti-androgen, was performed to estimate the clinical doses on 165 hormone untreated or treated patients with prostatic cancer. The hormone-untreated patients were given orally flutamide of 90, 375, 750 or 1,125 mg/day in three divided doses daily for 12

Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

We compared the efficacy and safety of the gonadotropin-releasing hormone analogue, leuprolide (1 mg subcutaneously daily), with diethylstilbestrol (DES, 3 mg by mouth daily) in patients with prostate cancer and distant metastases (Stage D2) who had not previously received systemic treatment.

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye